Opinion and Evidence in Respiratory Medicine
- PDF / 85,758 Bytes
- 3 Pages / 612 x 790.56 pts Page_size
- 84 Downloads / 162 Views
Am J Respir Med 2003; 2 (3): 283-285 1175-6365/03/0003-0283/$30.00/0 © Adis Data Information BV 2003. All rights reserved.
Opinion and Evidence in Respiratory Medicine Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283 1. Inhaled Glucocorticoids Versus Oral Leukotriene Antagonists in Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283 2. VPAC2 Receptor, RO 251553, Shows Promise in Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283 3. Emerging Therapies For Primary Pulmonary Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284 4. Low-Dose Budesonide Beneficial in Mild Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284 5. Montelukast: Addition to Fluticasone Not Beneficial in Mild Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285
Abstract
Respiratory Medicine is a vast and evolving area for researchers, primary care physicians and specialists. To help keep you up-to-date with the latest advances worldwide on all aspects of drug therapy and management of respiratory disorders, this section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly1. The following reports are selected from the latest issues, summarizing the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse reaction news, and expert opinion pieces published across a broad range of literature sources.
1. Inhaled Glucocorticoids Versus Oral Leukotriene Antagonists in Asthma In adult patients with asthma, exacerbations requiring systemic glucocorticoids are more effectively prevented by treatment with inhaled glucocorticoids than oral leukotriene antagonists, according to a meta-analysis by an investigator from Canada. The analysis included 13 trials in which patients with mild-tomoderate asthma were randomised to receive inhaled glucocorticoids or oral leukotriene antagonists for ≥28 days. A significantly greater proportion of patients treated with leukotriene antagonists experienced an exacerbation requiring systemic glucocorticoids, compared with patients treated with inhaled glucocorticoids (11.6% vs 6.2%). Furthermore, within 6 weeks of treatment, inhaled glucocorticoids were associated with significantly greater improvements in FEV1, morning peak expiratory flow rate and incidence of nocturnal awakenings, compared with leukotriene antagonists. In addition, there were significantly greater decreases in the use of rescue β2-adrenoceptor agonists an
Data Loading...
